With increasing numbers of anticancer drugs requiring testing, new adaptive model-based phase I trial designs can improve on current practice by exploring a wider range of dose combinations than standard phase I methods. In this Review, the authors describe the methods available as well as the opportunities and challenges faced in dual-agent phase I trials.
- Jennifer A. Harrington
- Graham M. Wheeler
- Duncan I. Jodrell